Abstract
Background Elevated hippocampal perfusion has been observed in people at clinical high-risk for psychosis (CHR-P). Preclinical evidence suggests that hippocampal hyperactivity is central to the pathophysiology of psychosis, and that prophylactic treatment with diazepam during adolescence can prevent the development of psychosis-relevant phenotypes. Here we examined whether diazepam normalises hippocampal perfusion in CHR-P individuals.
Methods Using a randomised, double-blind, placebo-controlled, crossover design, 24 CHR-P individuals were assessed with MRI on two occasions, once following a single oral dose of diazepam (5 mg) and once following placebo. Regional cerebral blood flow (rCBF) was measured using 3D pseudo-continuous arterial spin labelling and sampled in native space using participant-specific hippocampus/subfield masks (CA1, subiculum, CA4/dentate gyrus). Twenty-one healthy controls (HC) were scanned using the same acquisition sequence, but without administration of diazepam or placebo. Mixed-design ANCOVAs and linear mixed-effects models were used to examine the effects of group (CHR-P placebo/diazepam vs. HC) and condition (CHR-P diazepam vs. placebo) on rCBF in the hippocampus as a whole and by subfield.
Results Under the placebo condition, CHR-P individuals (mean[±SD] age: 24.1[±4.8] years, 15F) showed significantly elevated rCBF compared to HC (mean[±SD] age: 26.5[±5.1] years, 11F) in the hippocampus (F(1,36)=8.2, pFDR=0.004) and across its subfields (all pFDR<0.001). Following diazepam, rCBF in the hippocampus (and subfields, all pFDR<0.001) was significantly reduced (t(69)=-5.1, pFDR<0.001) and normalised to HC levels (F(1,41)=0.3, pFDR=0.225).
Conclusions Diazepam can normalise hippocampal hyperperfusion in CHR-P individuals, consistent with evidence implicating medial temporal GABAergic dysfunction in the pathophysiology of psychosis.
Competing Interest Statement
GM has received consulting fees from Boehringer Ingelheim. AE has received consulting fees from Leal Therapeutics. AAG has received funds from Lundbeck, Pfizer, Lilly, Roche, Janssen, Alkermes, Newron, Takeda and Merck. SCRW has recently received research funding from Boehringer Ingelheim and GE Healthcare to perform investigator-led research. All other authors have no financial disclosures or conflicts of interest.
Clinical Trial
NCT06190483
Funding Statement
This is independent research funded by the Wellcome Trust & The Royal Society (grant number 202397/Z/16/Z to GM) and carried out at the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre (BRC). NRL is supported by an MRC DTP PhD studentship. LAJ is supported by an MRC Clinical Research Training Fellowship (MR/T028084/1). PFP is supported by the European Union funding within the MUR PNRR Extended Partnership initiative on Neuroscience and Neuropharmacology (Project no. PE00000006 CUP H93C22000660006 [MNESYS, A multiscale integrated approach to the study of the nervous system in health and disease]). TJR Is supported by an MRC Clinical Research Training Fellowship, MR/W015943/1. AAG is supported by the National Institute of Mental Health (USPHS MH57440).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study had full ethical approval from the National Health Service UK Research Ethics Committee and was carried out at Kings College London, UK.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data will be made freely available upon publication (10.6084/m9.figshare.24763839), including i) mean rCBF values per subject per ROI per condition, and ii) coding scripts for the MRI preprocessing pipeline (run in Unix/shell) and generation of figures (run in R).
